These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 20643712)

  • 1. New drugs should be judged on "willingness to pay" basis, says leading economist.
    Wise J
    BMJ; 2010 Jul; 341():c3899. PubMed ID: 20643712
    [No Abstract]   [Full Text] [Related]  

  • 2. From evidence assessments to coverage decisions?: the case example of glinides in Germany.
    Kreis J; Busse R
    Health Policy; 2012 Jan; 104(1):27-31. PubMed ID: 22136812
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identifying factors that affect patients' willingness to pay for inhaled insulin.
    Pinto SL; Holiday-Goodman M; Black CD; Lesch D
    Res Social Adm Pharm; 2009 Sep; 5(3):253-61. PubMed ID: 19733826
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of type 2 diabetes mellitus on prescription medication burden and out-of-pocket healthcare expenses.
    Rodbard HW; Green AJ; Fox KM; Grandy S;
    Diabetes Res Clin Pract; 2010 Mar; 87(3):360-5. PubMed ID: 20047768
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Willingness-to-pay as a measure of benefits. Relevant questions in the context of public decisionmaking about health care programs.
    Gafni A
    Med Care; 1991 Dec; 29(12):1246-52. PubMed ID: 1745082
    [No Abstract]   [Full Text] [Related]  

  • 6. FDA needs more funding, NEJM says, amid questions about antidiabetes drug.
    Tanne JH
    BMJ; 2007 Aug; 335(7615):322. PubMed ID: 17703024
    [No Abstract]   [Full Text] [Related]  

  • 7. Ethnic differences in access to prescription medication because of cost in New Zealand.
    Jatrana S; Crampton P; Norris P
    J Epidemiol Community Health; 2011 May; 65(5):454-60. PubMed ID: 20466707
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New estimates of the demand for physical and mental health treatment.
    Meyerhoefer CD; Zuvekas SH
    Health Econ; 2010 Mar; 19(3):297-315. PubMed ID: 19350688
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is access sufficient? An examination of the effects of the MedShare program to expand access to prescription drugs for indigent populations.
    Shaw T; Carrozza M
    Eval Rev; 2008 Dec; 32(6):526-46. PubMed ID: 18981334
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The demand for health insurance coverage for tobacco dependence treatments: support for a benefit mandate and willingness to pay.
    Halpin HA; McMenamin SB; Shade SB
    Nicotine Tob Res; 2007 Dec; 9(12):1269-76. PubMed ID: 18058345
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Trends in outpatient prescription drug costs in diabetic patients in Germany, 1994-2004.
    Rathmann W; Haastert B; Icks A; Giani G
    Diabetes Care; 2007 Apr; 30(4):848-53. PubMed ID: 17392545
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Diabetes mellitus in sub-Saharan Africa: epidemiological aspects and management issues].
    Gning SB; Thiam M; Fall F; Ba-Fall K; Mbaye PS; Fourcade L
    Med Trop (Mars); 2007 Dec; 67(6):607-11. PubMed ID: 18300524
    [TBL] [Abstract][Full Text] [Related]  

  • 13. When it comes to new drugs, if providers and payers snooze, they lose.
    Cahn L
    Manag Care; 2015 Jan; 24(1):29, 34-8. PubMed ID: 25946791
    [No Abstract]   [Full Text] [Related]  

  • 14. The true cost and benefit of medication reduction.
    Aurigemma R
    Del Med J; 2009 Apr; 81(4):163-4. PubMed ID: 19552220
    [No Abstract]   [Full Text] [Related]  

  • 15. Drug therapy of cardiovascular risk factors: guidelines versus reality in primary health care service.
    Marković BB; Kranjcević K; Reiner Z; Blazeković SM; Spehar SS
    Croat Med J; 2005 Dec; 46(6):984-9. PubMed ID: 16342354
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thiazolidinediones and slowing the progression of diabetes.
    Jackson T; Aquilina A; Bloom J; Guerra-Garcia H; Salom I; Tzeel A; Kaminsky R
    Manag Care Interface; 2007 Aug; 20(8):29-34. PubMed ID: 18041348
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A one-time-only combination: Emergency medicine exports and the TRIPS agreement under Canada's access to medicines regime.
    Weber A; Mills L
    Health Hum Rights; 2010 Jun; 12(1):109-22. PubMed ID: 20930258
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PDP or MA-PD? Medicare part D enrollment decisions in CMS Region 25.
    Cline RR; Worley MM; Schondelmeyer SW; Schommer JC; Larson TA; Uden DL; Hadsall RS
    Res Social Adm Pharm; 2010 Jun; 6(2):130-42. PubMed ID: 20511112
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evidence-based benefit assessment of pharmaceuticals as a basis for rational and economical pharmaceutical therapy.
    Müller T
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():1-3. PubMed ID: 18987904
    [No Abstract]   [Full Text] [Related]  

  • 20. Value-based insurance design for diabetes mellitus: approaches to optimal pharmacoeconomic implementation.
    Fendrick AM
    Am J Manag Care; 2010 Dec; 16(11 Suppl):S314-22. PubMed ID: 21517647
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.